MX2021011563A - Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. - Google Patents

Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.

Info

Publication number
MX2021011563A
MX2021011563A MX2021011563A MX2021011563A MX2021011563A MX 2021011563 A MX2021011563 A MX 2021011563A MX 2021011563 A MX2021011563 A MX 2021011563A MX 2021011563 A MX2021011563 A MX 2021011563A MX 2021011563 A MX2021011563 A MX 2021011563A
Authority
MX
Mexico
Prior art keywords
compound
pharmaceutical composition
suppressant
isoindole
dihydro
Prior art date
Application number
MX2021011563A
Other languages
English (en)
Inventor
Yong Rae Hong
Jeong Eun Na
Im Sook Min
Hyun Ju Cha
Sool Ki Kwon
Seonggu Ro
Joong Myung Cho
Original Assignee
Crystalgenomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystalgenomics Inc filed Critical Crystalgenomics Inc
Publication of MX2021011563A publication Critical patent/MX2021011563A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención provee un compuesto seleccionado a partir del grupo que consiste en un compuesto de una fórmula (1) sus sales, ésteres, profármacos, hidratos, solvatos e isómeros del mismo, farmacéuticamente aceptables; un uso del compuesto para el tratamiento, alivio o prevención de enfermedades ocasionadas por actividad anómala o descontrolada de la proteínquinasa, y un uso del compuesto para la manufactura de un medicamento para el tratamiento, alivio o prevención de las enfermedades; una composición farmacéutica que comprende el compuesto como un ingrediente activo; y un método para el tratamiento, alivio o prevención de las enfermedades, utilizando el compuesto. El compuesto inventivo es útil para el tratamiento, alivio o prevención de las enfermedades ocasionadas por actividad anómala o descontrolada de la proteínquinasa.
MX2021011563A 2012-12-28 2013-12-26 Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. MX2021011563A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746980P 2012-12-28 2012-12-28
PCT/KR2013/012204 WO2014104757A1 (ko) 2012-12-28 2013-12-26 Btk 키나아제 억제제로서의 2,3-디하이드로-이소인돌-1-온 유도체 및 이를 함유하는 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2021011563A true MX2021011563A (es) 2022-10-10

Family

ID=51021712

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021011563A MX2021011563A (es) 2012-12-28 2013-12-26 Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
MX2015008396A MX2015008396A (es) 2012-12-28 2013-12-26 Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015008396A MX2015008396A (es) 2012-12-28 2013-12-26 Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.

Country Status (16)

Country Link
US (4) US9758508B2 (es)
EP (2) EP2940014B1 (es)
JP (2) JP6325573B2 (es)
KR (1) KR102009163B1 (es)
CN (1) CN104995184B (es)
AU (3) AU2013371146C1 (es)
BR (1) BR112015015477B1 (es)
CA (1) CA2896711C (es)
DK (1) DK2940014T3 (es)
ES (2) ES2929906T3 (es)
HK (1) HK1259355A1 (es)
MX (2) MX2021011563A (es)
PL (1) PL2940014T3 (es)
PT (1) PT2940014T (es)
RU (2) RU2671847C2 (es)
WO (1) WO2014104757A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3205654T3 (pl) 2010-05-20 2019-08-30 Array Biopharma, Inc. Związki makrocykliczne jako inhibitory kinazy TRK
US9758508B2 (en) * 2012-12-28 2017-09-12 Crystalgenomics, Inc. 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same
KR20180041135A (ko) 2015-07-16 2018-04-23 어레이 바이오파마 인크. Ret 키나아제 억제제로서 치환된 피라졸로[1,5-a]피리딘 화합물
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JP2020511462A (ja) 2016-12-03 2020-04-16 ジュノー セラピューティクス インコーポレイテッド キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
EP3585778A4 (en) * 2017-02-21 2020-12-02 Aptose Biosciences Inc. METHODS OF TREATING PATIENTS WITH HEMATOLOGICAL MALIGNACIES
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
JP7061195B2 (ja) 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物
CA3087354C (en) 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
AU2019387508A1 (en) * 2018-11-30 2021-06-10 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
JP2024509192A (ja) * 2021-03-05 2024-02-29 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL367064A1 (en) * 2001-04-12 2005-02-21 F.Hoffmann-La Roche Ag Dihydro-benzo [b] [1,4] diazepin-2-one derivatives as mglur2 antagonists ii
MXPA05013076A (es) * 2003-06-02 2006-03-09 Abbott Lab Compuestos de isoindolina-1-ona como inhibidores de cinasa.
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
AU2006237920A1 (en) * 2005-04-19 2006-10-26 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound
US20070161648A1 (en) * 2005-10-14 2007-07-12 Hughes Terry V Substituted dihydro-isoindolones useful in treating kinase disorders
EP1998777A1 (en) * 2006-03-20 2008-12-10 F. Hoffmann-La Roche AG Methods of inhibiting btk and syk protein kinases
WO2008047831A1 (fr) * 2006-10-17 2008-04-24 Kyowa Hakko Kirin Co., Ltd. Inhibiteurs de JAK
EP2205564B1 (en) 2007-10-23 2014-07-30 F. Hoffmann-La Roche AG Novel kinase inhibitors
WO2012014017A1 (en) 2010-07-30 2012-02-02 Poly Medicure Limited Catheter introducer
WO2012047017A2 (ko) * 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
US9758508B2 (en) * 2012-12-28 2017-09-12 Crystalgenomics, Inc. 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase

Also Published As

Publication number Publication date
MX2015008396A (es) 2016-04-15
EP3428161A1 (en) 2019-01-16
US20210009565A1 (en) 2021-01-14
AU2020201431B2 (en) 2021-07-22
JP6596537B2 (ja) 2019-10-23
ES2696700T3 (es) 2019-01-17
PL2940014T3 (pl) 2019-03-29
ES2929906T3 (es) 2022-12-02
US10604508B2 (en) 2020-03-31
AU2013371146B2 (en) 2018-05-10
KR20160058720A (ko) 2016-05-25
AU2018214134B2 (en) 2020-03-12
AU2013371146A1 (en) 2015-07-16
EP3428161B1 (en) 2022-09-07
WO2014104757A1 (ko) 2014-07-03
CN104995184B (zh) 2018-01-02
PT2940014T (pt) 2018-11-28
US20220380346A1 (en) 2022-12-01
CA2896711C (en) 2019-12-31
RU2015124381A (ru) 2017-02-01
JP6325573B2 (ja) 2018-05-16
CN104995184A (zh) 2015-10-21
US9758508B2 (en) 2017-09-12
EP2940014A4 (en) 2016-06-22
CA2896711A1 (en) 2014-07-03
RU2018138028A (ru) 2019-03-21
US11230539B2 (en) 2022-01-25
HK1259355A1 (zh) 2019-11-29
RU2671847C2 (ru) 2018-11-07
EP2940014A1 (en) 2015-11-04
AU2013371146C1 (en) 2019-01-17
EP2940014B1 (en) 2018-09-26
KR102009163B1 (ko) 2019-08-09
US20150336934A1 (en) 2015-11-26
JP2018109069A (ja) 2018-07-12
AU2018214134A1 (en) 2018-08-30
BR112015015477A2 (pt) 2017-07-11
BR112015015477B1 (pt) 2022-07-12
JP2016504351A (ja) 2016-02-12
AU2020201431A1 (en) 2020-03-19
US20170362205A1 (en) 2017-12-21
DK2940014T3 (en) 2018-12-10

Similar Documents

Publication Publication Date Title
MX2015008396A (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
NZ708593A (en) Novel pyrazole derivative
EA033689B9 (ru) Ингибиторы g12c kras
MY163235A (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
WO2012047017A3 (ko) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
MY161001A (en) Tetrahydrocarboline Derivative
MX2013012588A (es) Inhibidores de cinasa.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
IN2014DN05869A (es)
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
PH12015501945B1 (en) Formulations of organic compounds
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
IN2015MN00045A (es)
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
JOP20180071A1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
MX365021B (es) Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo.